| Version 2.1.0.0 |
|
|
| Grant Number: | 1R43CA096276-01 |
| PI Name: | ABATO, PAUL |
| PI Email: | |
| PI Title: | SENIOR SCIENTIST |
| Project Title: | Validation of Prostate Cancer Oncogenes |
Abstract: DESCRIPTION (provided by applicant): We propose the creation of a comprehensive tissue microarray consisting of all pathologic stages of adenocarcinoma of the prostate as a tool for testing promising cellular markers - genes and proteins that will serve as an aid to researchers in validating the potential usefulness of any given marker. We propose to create this tissue microarray and test its usefulness by observing the differential expression of two specific markers -prostate stem-cell antigen (PSCA) and p27 protein. PSCA is a cell surface antigen expressed in normal prostate and overexpressed in prostate cancer tissues directly correlating with Gleason score. Conversely, an absence of or decrease in the p27 protein in prostate cancer biopsies prior to treatment has been associated with a shorter time to recurrent disease after curative therapy. Currently, there exists no comprehensive data for either of these markers relative to all pathologic stages of prostate cancer. Consequently, we propose to utilize tissue microarray technology to rapidly screen multiple prostate cancer samples for the levels of these markers. Correlations to metastatic potential and patient outcomes will be determined. PROPOSED COMMERCIAL APPLICATION: A robust and reliable method for determining the metastatic potential of prostate cancers has been elusive. Use of high throughput tissue-based screening will accelerate the process of validating potential markers like PCAS and p27. The expansion of these tissue-based techniques to "pharmacoproteomics" will offer opportunities for the fabrication, use, and analysis of high-throughput tissue-based assays.
Thesaurus Terms:
adenocarcinoma, biomarker, microarray technology, oncogene, prostate neoplasm, technology /technique development, tumor antigen
antibody, cell cycle protein, enzyme inhibitor, protein kinase
clinical research, fluorescent in situ hybridization, high throughput technology, human genetic material tag, immunocytochemistry
| Institution: | EIKOS, INC. |
| 2 MASTER DR, STE 2 | |
| FRANKLIN, MA 02038 | |
| Fiscal Year: | 2002 |
| Department: | |
| Project Start: | 16-SEP-2002 |
| Project End: | 31-AUG-2003 |
| ICD: | NATIONAL CANCER INSTITUTE |
| IRG: | ZRG1 |